GFM
CCCC icon

GF Fund Management’s C4 Therapeutics CCCC Stock Holding History

GF Fund Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.69K Buy
2,165
+262
+14% +$617 ﹤0.01% 601
2025
Q4 		$3.63K Buy
1,903
+440
+30% +$1.04K ﹤0.01% 631
2025
Q3 		$3.25K Sell
1,463
-288
-16% -$691 ﹤0.01% 615
2025
Q2 		$2.5K Hold
1,751
– – ﹤0.01% 646
2025
Q1 		$2.8K Buy
1,751
+269
+18% +$802 ﹤0.01% 644
2024
Q4 		$5.33K Buy
+1,482
New +$7.37K ﹤0.01% 609

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GF Fund Management's CCCC Position: Q1 2026 in Review

GF Fund Management increased its C4 Therapeutics (CCCC) stake by 14% in Q1 2026, buying an estimated $617 and bringing the position to 2,165 shares worth $5.69K. The position accounts for ﹤0.01% of the portfolio, ranked #601.

GF Fund Management first reported a position in CCCC in Q4 2024 and has held it in 6 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • GF Fund Management held 2,165 shares of C4 Therapeutics worth $5.69K as of Q1 2026.
  • GF Fund Management bought 262 C4 Therapeutics shares in Q1 2026, an estimated $617.
  • C4 Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #601 holding.
  • GF Fund Management first reported a position in C4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.